E Fernström1, K Minta2, U Andreasson2,3, Å Sandelius2, P Wasling4, A Brinkmalm2,3, K Höglund2,3, K Blennow2,3, J Nyman1, H Zetterberg2,3,5,6, M Kalm7. 1. Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden. 2. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology at the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden. 3. Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Gothenburg, Sweden. 4. Department of Physiology, Institute of Neuroscience and Physiology at the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden. 5. Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK. 6. UK Dementia Research Institute at UCL, London, UK. 7. Department of Pharmacology, Institute of Neuroscience and Physiology at the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Abstract
BACKGROUND: Advances in the treatment of brain tumours have increased the number of long-term survivors, but at the cost of side effects following cranial radiotherapy ranging from neurocognitive deficits to outright tissue necrosis. At present, there are no tools reflecting the molecular mechanisms underlying such side effects, and thus no means to evaluate interventional effects after cranial radiotherapy. Therefore, fluid biomarkers are of great clinical interest. OBJECTIVE: Cerebrospinal fluid (CSF) levels of proteins involved in inflammatory signalling, synaptic plasticity and extracellular matrix (ECM) integrity were investigated following radiotherapy to the brain. METHODS: Patients with small-cell lung cancer (SCLC) eligible for prophylactic cranial irradiation (PCI) were asked to participate in the study. PCI was prescribed either as 2 Gy/fraction to a total dose of 30 Gy (limited disease) or 4 Gy/fraction to 20 Gy (extensive disease). CSF was collected by lumbar puncture at baseline, 3 months and 1 year following PCI. Protein concentrations were measured using immunobased assays or mass spectrometry. RESULTS: The inflammatory markers IL-15, IL-16 and MCP-1/CCL2 were elevated in CSF 3 months following PCI compared to baseline. The plasticity marker GAP-43 was elevated 3 months following PCI, and the same trend was seen for SNAP-25, but not for SYT1. The investigated ECM proteins, brevican and neurocan, showed a decline following PCI. There was a strong correlation between the progressive decline of soluble APPα and brevican levels. CONCLUSION: To our knowledge, this is the first time ECM-related proteins have been shown to be affected by cranial radiotherapy in patients with cancer. These findings may help us to get a better understanding of the mechanisms behind side effects following radiotherapy.
BACKGROUND: Advances in the treatment of brain tumours have increased the number of long-term survivors, but at the cost of side effects following cranial radiotherapy ranging from neurocognitive deficits to outright tissue necrosis. At present, there are no tools reflecting the molecular mechanisms underlying such side effects, and thus no means to evaluate interventional effects after cranial radiotherapy. Therefore, fluid biomarkers are of great clinical interest. OBJECTIVE: Cerebrospinal fluid (CSF) levels of proteins involved in inflammatory signalling, synaptic plasticity and extracellular matrix (ECM) integrity were investigated following radiotherapy to the brain. METHODS:Patients with small-cell lung cancer (SCLC) eligible for prophylactic cranial irradiation (PCI) were asked to participate in the study. PCI was prescribed either as 2 Gy/fraction to a total dose of 30 Gy (limited disease) or 4 Gy/fraction to 20 Gy (extensive disease). CSF was collected by lumbar puncture at baseline, 3 months and 1 year following PCI. Protein concentrations were measured using immunobased assays or mass spectrometry. RESULTS: The inflammatory markers IL-15, IL-16 and MCP-1/CCL2 were elevated in CSF 3 months following PCI compared to baseline. The plasticity marker GAP-43 was elevated 3 months following PCI, and the same trend was seen for SNAP-25, but not for SYT1. The investigated ECM proteins, brevican and neurocan, showed a decline following PCI. There was a strong correlation between the progressive decline of soluble APPα and brevican levels. CONCLUSION: To our knowledge, this is the first time ECM-related proteins have been shown to be affected by cranial radiotherapy in patients with cancer. These findings may help us to get a better understanding of the mechanisms behind side effects following radiotherapy.
Authors: Johanna Nilsson; Nicholas J Ashton; Andrea L Benedet; Laia Montoliu-Gaya; Johan Gobom; Tharick A Pascoal; Mira Chamoun; Erik Portelius; Andreas Jeromin; Muriel Mendes; Henrik Zetterberg; Pedro Rosa-Neto; Ann Brinkmalm; Kaj Blennow Journal: Alzheimers Res Ther Date: 2022-06-04 Impact factor: 8.823
Authors: Mica T M Clarke; Ann Brinkmalm; Martha S Foiani; Ione O C Woollacott; Carolin Heller; Amanda Heslegrave; Ashvini Keshavan; Nick C Fox; Jonathan M Schott; Jason D Warren; Kaj Blennow; Henrik Zetterberg; Jonathan D Rohrer Journal: Alzheimers Res Ther Date: 2019-12-17 Impact factor: 6.982
Authors: Wilhelm Hußler; Lukas Höhn; Christopher Stolz; Stefan Vielhaber; Cornelia Garz; Friedhelm C Schmitt; Eckart D Gundelfinger; Stefanie Schreiber; Constanze I Seidenbecher Journal: Front Cell Neurosci Date: 2022-04-11 Impact factor: 5.505
Authors: Faisal Hayat Nazir; Bruno Becker; Ann Brinkmalm; Kina Höglund; Åsa Sandelius; Petra Bergström; Tugce Munise Satir; Annika Öhrfelt; Kaj Blennow; Lotta Agholme; Henrik Zetterberg Journal: Neurochem Int Date: 2018-10-18 Impact factor: 3.921